| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BMS-536924 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.002 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | -0.14 | 0.003 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.13 | 0.005 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.09 | 0.006 |
| mRNA | ZG-10 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.007 |
| mRNA | MS-275 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.009 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | 0.1 | 0.009 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.097 | 0.01 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.13 | 0.01 |
| mRNA | 17-AAG | FIMM | pan-cancer | AAC | -0.46 | 0.01 |